SB 204990
Tocris Bioscience, part of Bio-Techne | Catalog # 4962
ATP citrate lyase (ACLY) inhibitor
Key Product Details
Description
ATP citrate lyase (ACLY) inhibitor
Product Description
SB 204990 is an ATP citrate lyase (ACLY) inhibitor; it is a prodrug of SB 201076. SB 204990 inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Suppresses growth of cancer cells showing aerobic glycolysis in vitro and in vivo. Orally active.Licensing Information
Sold for research purposes under agreement from GlaxoSmithKlineProduct Specifications
Molecular Weight
389.27
Formula
C18H22Cl2O5
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
(3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid
CAS Number
154566-12-8
PubChem ID
10340264
InChI Key
YTRNLFYTHYWDAU-KDOFPFPSSA-N
SMILES
ClC(C=C(Cl)C=C2)=C2CCCCCC[C@@H](OC1=O)C[C@]1(O)CC(O)=O
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 38.93 | 100 | |
| Ethanol | 38.93 | 100 |
Preparing Stock Solutions
for SB 204990
The following data is based on the product molecular weight 389.27
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.57 mL | 12.84 mL | 25.69 mL |
| 5 mM | 0.51 mL | 2.57 mL | 5.14 mL |
| 10 mM | 0.26 mL | 1.28 mL | 2.57 mL |
| 50 mM | 0.05 mL | 0.26 mL | 0.51 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Gribble ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzy J.Med.Chem. 1998 PMID: 9733484
- Hatzivassiliou ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005 PMID: 16226706
- Pearce The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem.J. 1998 PMID: 9693110
Product Specific Notices for SB 204990
For research use only
Loading...
Loading...
Loading...